GENE ONLINE|News &
Opinion
Blog

2025-11-27|

Epigenetic Dysregulation of CNR1 and FAAH Linked to Endocannabinoid System Disruptions in Anorexia Nervosa

by GOAI
Share To

A recent study has identified a potential link between epigenetic dysregulation and disruptions in the endocannabinoid system in individuals with anorexia nervosa. Researchers, led by F. Gilardini, found that alterations in two key genes—CNR1 and FAAH—may contribute to dysfunction within the endocannabinoid system, which plays a critical role in regulating mood, appetite, and stress responses. The findings shed light on how genetic factors may influence the development or persistence of this complex eating disorder.

The study focused on examining the epigenetic regulation of CNR1 and FAAH, both of which are essential components of the endocannabinoid system. CNR1 encodes for cannabinoid receptor 1 (CB1), while FAAH is responsible for breaking down anandamide, a neurotransmitter involved in mood and appetite regulation. Researchers observed significant changes in the expression levels of these genes among individuals with anorexia nervosa compared to healthy controls. These findings suggest that disruptions in gene activity could impair normal functioning of the endocannabinoid system, potentially contributing to symptoms associated with anorexia nervosa. Further research is needed to explore how these genetic mechanisms interact with other biological and environmental factors involved in this condition.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: November 27, 2025

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Author
Related Post
AI-Driven Healthcare Transformation at Healthcare Expo Taiwan 2025
2025-12-05
LATEST
AI-Driven Healthcare Transformation at Healthcare Expo Taiwan 2025
2025-12-05
How AWS Cloud Is Transforming Global Smart Healthcare and Trusted Research Environments
2025-12-03
MedTex 2025: Taiwan as Gateway for AI-Driven Medical Innovation and Global Capital
2025-12-03
FDA CBER Director Vinay Prasad Issues November 2025 Memo Addressing Vaccine Development and Regulatory Challenges
2025-12-03
FDA to Review 16 Drug Applications Including 8 New Molecular Entities by Year-End
2025-12-03
Stephen Durso Named CEO of Altimmune Inc. as Vipin Garg Steps Down
2025-12-03
Janux Therapeutics Shares Halve Despite Positive Phase I Trial Results for Solid Tumor Therapy
2025-12-03
EVENT
2025-12-06
The 67th ASH Annual Meeting and Exposition
Orlando, Florida, USA
2025-12-04
2025 Healthcare+ Expo Taiwan
Taipei, Taiwan
Scroll to Top